Minds & Molecules: Lessons from Alzheimer's Research

Despite limited success with amyloid-targeting biologics, Alzheimer's disease (AD) remains a neurodegenerative disorder in dire need of new directions and new thinking to augment ongoing approaches. Instead of seeking a single "magic bullet" for AD, a multifaceted approach is more likely to lead to success. Targets involved in neuroinflammation have emerged for the treatment of AD.
00:23 Introduction
03:38 Ice-breaker questions
16:14 Presentation
48:21 Q&A
Presented by Donald Weaver Professor of Chemistry, Pharmaceutical Sciences and Medicine at the University of Toronto with host Dennis Koester, Director of Industry Research and Relations, Drug Hunter
Presented on June 13, 2024, as a Drug Hunter Flash Talk.
Sign up for future sessions here: drughunter.com/flash-talk-ser...

[@Mohakal777]

Thank you so much Dennis for bringing these great people to share their knowledge.

[@invictusfate7195]

Thank you for the nice presentation. Does this mean that current ABeta targeting therapeutics such as donanemab could lead to increased infections in patients under treatment?